Cargando…

Hydroxychloroquine reduces T cells activation recall antigen responses

BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowatsch, Monika M., Lajoie, Julie, Mwangi, Lucy, Omollo, Kenneth, Oyugi, Julius, Hollett, Natasha, Kimani, Joshua, Fowke, Keith R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395872/
https://www.ncbi.nlm.nih.gov/pubmed/37531383
http://dx.doi.org/10.1371/journal.pone.0287738
_version_ 1785083674523336704
author Kowatsch, Monika M.
Lajoie, Julie
Mwangi, Lucy
Omollo, Kenneth
Oyugi, Julius
Hollett, Natasha
Kimani, Joshua
Fowke, Keith R.
author_facet Kowatsch, Monika M.
Lajoie, Julie
Mwangi, Lucy
Omollo, Kenneth
Oyugi, Julius
Hollett, Natasha
Kimani, Joshua
Fowke, Keith R.
author_sort Kowatsch, Monika M.
collection PubMed
description BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activities, such as hydroxychloroquine (HCQ), could also impact their ability to respond to a COVID vaccine and vaccines in general. METHODS: Heathy donors were given 200mg of HCQ daily for 6-weeks to assess HCQs impact on the systemic T cells and humoral immune response. Peripheral blood mononuclear cells (PBMC) and plasma were obtained at baseline and 6-weeks after starting daily HCQ. Flow cytometry assays were designed to determine changes in T cell activation and T cell responses. Bead array multiplex were used to analyse antibodies and cytokine levels before and after HCQ intake. RESULTS: As anticipated, HCQ treatment decreased ex vivo T cell activation. We observed a decrease in CD4(+)CD161(-) expressing CCR5 (p = 0.015) and CD69 (p = 0.004) as well as in CD8(+)CCR5(+) (p = 0.003), CD8(+)CD161(+)CCR5(+) (p = 0.002) and CD8(+)CD161(+)CD95(+) (p = 0.004). Additionally, HCQ decreased the proportion of Th17 expressing CD29 (p = 0.019), a subset associated with persistent inflammation. The proportion of T regulatory cells expressing the inhibitory molecule TIGIT was also reduced by HCQ (p = 0.003). As well, T cells from people on HCQ were less responsive to activation and cytokine production following stimulation with recall antigens and memory T cells were less likely to produce both IFNγ and TNFα following stimulation. CONCLUSION: This study shows HCQ is associated with lower T cell activation and decreased T cell cytokine production. While this study was not performed with the intent of looking at COVID vaccine response, it does provide important information about the changes in immune response that may occur in patient taking HCQ as a treatment for their autoimmune disease.
format Online
Article
Text
id pubmed-10395872
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-103958722023-08-03 Hydroxychloroquine reduces T cells activation recall antigen responses Kowatsch, Monika M. Lajoie, Julie Mwangi, Lucy Omollo, Kenneth Oyugi, Julius Hollett, Natasha Kimani, Joshua Fowke, Keith R. PLoS One Research Article BACKGROUND: In the context of the current COVID-19 pandemic, there is still limited information about how people suffering from autoimmune diseases respond to the different COVID vaccines. The fact that they are taking an immunosuppressant or other drugs that aim to decrease the immune system activities, such as hydroxychloroquine (HCQ), could also impact their ability to respond to a COVID vaccine and vaccines in general. METHODS: Heathy donors were given 200mg of HCQ daily for 6-weeks to assess HCQs impact on the systemic T cells and humoral immune response. Peripheral blood mononuclear cells (PBMC) and plasma were obtained at baseline and 6-weeks after starting daily HCQ. Flow cytometry assays were designed to determine changes in T cell activation and T cell responses. Bead array multiplex were used to analyse antibodies and cytokine levels before and after HCQ intake. RESULTS: As anticipated, HCQ treatment decreased ex vivo T cell activation. We observed a decrease in CD4(+)CD161(-) expressing CCR5 (p = 0.015) and CD69 (p = 0.004) as well as in CD8(+)CCR5(+) (p = 0.003), CD8(+)CD161(+)CCR5(+) (p = 0.002) and CD8(+)CD161(+)CD95(+) (p = 0.004). Additionally, HCQ decreased the proportion of Th17 expressing CD29 (p = 0.019), a subset associated with persistent inflammation. The proportion of T regulatory cells expressing the inhibitory molecule TIGIT was also reduced by HCQ (p = 0.003). As well, T cells from people on HCQ were less responsive to activation and cytokine production following stimulation with recall antigens and memory T cells were less likely to produce both IFNγ and TNFα following stimulation. CONCLUSION: This study shows HCQ is associated with lower T cell activation and decreased T cell cytokine production. While this study was not performed with the intent of looking at COVID vaccine response, it does provide important information about the changes in immune response that may occur in patient taking HCQ as a treatment for their autoimmune disease. Public Library of Science 2023-08-02 /pmc/articles/PMC10395872/ /pubmed/37531383 http://dx.doi.org/10.1371/journal.pone.0287738 Text en © 2023 Kowatsch et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kowatsch, Monika M.
Lajoie, Julie
Mwangi, Lucy
Omollo, Kenneth
Oyugi, Julius
Hollett, Natasha
Kimani, Joshua
Fowke, Keith R.
Hydroxychloroquine reduces T cells activation recall antigen responses
title Hydroxychloroquine reduces T cells activation recall antigen responses
title_full Hydroxychloroquine reduces T cells activation recall antigen responses
title_fullStr Hydroxychloroquine reduces T cells activation recall antigen responses
title_full_unstemmed Hydroxychloroquine reduces T cells activation recall antigen responses
title_short Hydroxychloroquine reduces T cells activation recall antigen responses
title_sort hydroxychloroquine reduces t cells activation recall antigen responses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395872/
https://www.ncbi.nlm.nih.gov/pubmed/37531383
http://dx.doi.org/10.1371/journal.pone.0287738
work_keys_str_mv AT kowatschmonikam hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT lajoiejulie hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT mwangilucy hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT omollokenneth hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT oyugijulius hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT hollettnatasha hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT kimanijoshua hydroxychloroquinereducestcellsactivationrecallantigenresponses
AT fowkekeithr hydroxychloroquinereducestcellsactivationrecallantigenresponses